NIVEA experienced a challenging Q1 with a 7% decline amid market headwinds, but strategic rebalancing initiatives show early signs of restoring growth, supported by strong derma performance and targeted portfolio adjustments.

• Group organic net sales declined 4.6%, with NIVEA dropping 7%, primarily due to market conditions, lapping prior-year peaks, and temporary disruptions.
• Derma outperformed with 8.2% organic growth, led by innovations like Thiamidol and successful expansions in North America, Brazil, and China.
• La Prairie faced headwinds from U.S. department store and travel retail disruptions, resulting in a 14.9% decline, though retail demand remains positive.
• NIVEA's rebalancing focuses on expanding face, body, and deodorant categories, with early market share gains in emerging markets and Europe.
• Innovation remains a pillar, with NIVEA Epicelline on track, showing promising repurchase trends aligned with Eucerin’s success.